Additional information relating to breastfeeding
To be used in conjunction with individual drug entries for specific information and guidance.
Orlistat is the only drug licensed for the treatment of obesity after dietary interventions alone have failed. It should be used in conjunction with other lifestyle changes, which are unlikely to impact on breastfeeding.
Several drugs previously used to treat obesity are not included in this section as they have been withdrawn from the market due to adverse effects or ineffectiveness. They include phentermine, diethylpropion, sibutramine, dexfenfluramine and fenfluramine.